UCB’s Rystiggo gains Japanese approval
Belgium’s largest drugmaker UCB (Euronext: UCB) today revealed that it has received approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for at-home self-administration with infusion pump or a new manual push syringe method for Rystiggo (rozanolixizumab).
UCB explained that, with this approval, people living with generalized Myasthenia Gravis (gMG) can now self-administer Rystiggo at home using either a manual push or syringe pump method, following training from a healthcare professional. The company’s shares edged up 2.2% to 155.00 euros on the news.
Complementing this approval, UCB Japan will launch a home delivery service for Rystiggo, including portable syringe pumps, as part of the ONWARD program. ONWARD is a global UCB patient support program designed to assist individuals living with rare diseases like gMG, offering features such as symptom tracking, support by dedicated Care Coordinators for each patient, and 24/7 online tools.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze